Verona pharma to present six analyses of the phase 3 enhance studies in copd at chest 2024

Verona pharma announces four oral presentations and two posters on analyses from its phase 3 enhance studies with ohtuvayre (ensifentrine) at chest 2024.

VRNA Ratings Summary

VRNA Quant Ranking